Table 3 CSF ELISA testing of patients (DCM) and controls (TAAA).

From: Decreased angiogenesis as a possible pathomechanism in cervical degenerative myelopathy

CSF ELISA testing

DCM

TAAA

P*

ηp2

M [SD]

M[SD]

Angiogenic mediators

N = 24

N = 23

  

 Angiopoietin 2 (pg/ml)

267.1 [81.9]

408.6 [177.1]

< .001

.22

 VEGF C (pg/ml)

152.2 [96.1]

222.4 [140.3]

.04

.09

 VEGF A (pg/ml)

15.3 [8.5]

15.4 [13.0]

.98

.00

Inflammatory mediators

N = 21

N = 27

  

 IL1 beta (pg/ml)

1.7 [4.6]

1.2 [1.0]

.60

.01

 IL 8 (pg/ml)

72.6 [74.8]

291.1 [721.8]

.14

.05

 Rantes (pg/ml)

3.2 [10.0]

2.8 [3.3]

.88

.00

  1. CSF cerebrospinal fluid, DCM degenerative cervical myelopathy, pg/ml picogram per milliliter, M mean, SD standard deviation, TAAA thoracic-abdominal aortic aneurysm.
  2. *p values reflect the univariate post-hoc between group tests revealed by the MANOVAs; ηp2 = partial eta squared effect size.
  3. Bold values indicate significance level of p < .05.
Back to article page